2023
DOI: 10.1016/j.arcmed.2023.06.002
|View full text |Cite
|
Sign up to set email alerts
|

Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 119 publications
0
2
0
Order By: Relevance
“…Mitochondrial homeostasis is associated with progeria phenotypes in HGPS cells, but the mechanistic link remains largely elusive (Cisneros et al., 2023 ). Our results demonstrate that mitophagy defects contribute to the aging hallmarks in HGPS cells.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Mitochondrial homeostasis is associated with progeria phenotypes in HGPS cells, but the mechanistic link remains largely elusive (Cisneros et al., 2023 ). Our results demonstrate that mitophagy defects contribute to the aging hallmarks in HGPS cells.…”
Section: Resultsmentioning
confidence: 99%
“…This mutation leads to the production of progerin, a truncated variant of Lamin A (Ahmed et al., 2018 ). The only drug approved by the US Food and Drug Administration (FDA) for HGPS treatment is Lonafarnib, which targets progerin synthesis (Cisneros et al., 2023 ). However, Lonafarnib causes widespread severe side effects in clinical use, including vomiting, diarrhea, and infection (Gordon et al., 2018 ).…”
Section: Introductionmentioning
confidence: 99%